Abstract
Background and Aims: The inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) efficiently reduces plasma cholesterol levels. This meta-analysis aimed at investigating the efficacy on cardiovascular (CV) outcomes and the safety of treatment with anti-PCSK9 monoclonal antibodies (mAbs) in all published randomized clinical trials (RCTs).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
